Testing sacituzumab tirumotecan with pembrolizumab before surgery for early breast cancer
Tests sacituzumab tirumotecan with chemotherapy in adults with early high-risk breast cancer.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Abilene, Altamonte Springs, Baltimore, Boston, Burbank, Carterville, Charleston, Cincinnati, Clovis, Dallas, Denver, Flower Mound, Fort Myers, Fort Wayne, Fort Worth, Fullerton, Gilbert, Grand Forks, Grand Junction, Greenville, Hackensack, Hialeah, Houston, Indianapolis, Jacksonville, Kansas City, Knoxville, Las Vegas, Lincoln, Long Beach, Lubbock, Madison, Midlothian, Mountain View, Murray, Nashville, New Brunswick, New Orleans, Newnan, Newport Beach, Norfolk, Phoenix, Reno, Roanoke, San Antonio, Seattle, Shreveport, Sioux Falls, Spokane, St Louis, St. Petersburg, Tacoma, Tigard, Tucson, Westbrook, Whittier, and Yankton, United StatesSee the 64 sitesAlso in 40 other countries, 276 sites
- Trial code
- NCT06966700
- EU 2024-520190-12-00
- JRCT2031250231
- U1111-1316-7898
- Registry title
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 2,400 people, planned
- Started
- 30 Jun 2025
- Expected to end
- 29 Dec 2034
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sacituzumab tirumotecan
- Pembrolizumab
- Rescue Medication
- Carboplatin
- Paclitaxel
- Doxorubicin
- Epirubicin
- Cyclophosphamide
- Capecitabine
- Olaparib
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with new, untreated, high-risk, early-stage breast cancer that is triple-negative or hormone receptor-low positive and HER2-negative.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- High-risk, early-stage breast cancer that has not spread (M0), with tumor and lymph node stage cT1c N1-N2, cT2 N0-N2, cT3 N0-N2 or cT4a-d N0-N2.
- Earlier treatment
- No earlier treatment for this breast cancer, including radiation, drug treatment or definitive surgery. No earlier anti-PD-1, anti-PD-L1 or anti-PD-L2 therapy.
- Biomarker or test result
- Triple-negative breast cancer, or HR-low positive/HER2-negative breast cancer (estrogen receptor expression in 1% to 10% of cells), confirmed by a central laboratory.
Main reasons for not taking part
- Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3)
- Earlier treatment for this breast cancer, including radiation, drug treatment or definitive surgery
- Earlier excisional biopsy of the tumor, axillary lymph node dissection or sentinel lymph node biopsy
- Earlier treatment with a TROP2-targeted antibody-drug conjugate or a topoisomerase I inhibitor-containing antibody-drug conjugate
- History of or current pneumonitis or interstitial lung disease that needed steroids
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per AJCC 8th edition criteria as assessed by the physician investigator based on radiological and/or clinical assessment:; cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; cT4a-d, N0-N2
- The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2- as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
- Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1)
- Demonstrates adequate organ function
Who cannot take part
- Has received any prior treatment, including radiation, systemic therapy,and/or definitive surgery for currently diagnosed breast cancer
- Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment
- Received prior systemic anticancer therapy including investigational agents within 4 weeks before C1D1
- Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137)
- Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC)
- Received prior treatment with a topoisomerase I inhibitor-containing ADC
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
- Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement
- Known additional malignancy that is progressing or has required active treatment within the past 5 years
- Uncontrolled systemic disease
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids, has current pneumonitis/interstitial lung disease or has suspected interstitial lung disease (ILD) or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
- The main exclusion criteria include but are not limited to the following:
Where in United States
Also in 40 other countries, 276 sites
- Hendrick Medical Center (Site 0009)Abilene, United StatesContact: Toll Free NumberNo longer taking part
- AdventHealth Medical Group Oncology and Hematology at Altamonte (Site 0044)Altamonte Springs, United StatesContact: Study CoordinatorTaking people
- Mercy Medical Center - Baltimore (Site 0015)Baltimore, United StatesContact: Study CoordinatorTaking people
- Dana Farber Cancer Institute (Site 0090)Boston, United StatesContact: Study CoordinatorTaking people
- Massachusetts General Hospital Cancer Center (Site 0091)Boston, United StatesContact: Study CoordinatorTaking people
- Roy and Patricia Disney Family Cancer Center (Site 0055)Burbank, United StatesContact: Study CoordinatorTaking people
- Southern Illinois Hospital Services (Site 9554)Carterville, United StatesContact: Study CoordinatorTaking people
- Medical University of South Carolina-Hollings Cancer Center (Site 0016)Charleston, United StatesContact: Study CoordinatorTaking people
- Good Samaritan Hospital-TriHealth Cancer institute (Site 0027)Cincinnati, United StatesContact: Study CoordinatorTaking people
- Community Cancer Institute (Site 0100)Clovis, United StatesContact: Study CoordinatorTaking people
- Texas Oncology - DFW (Site 8009)Dallas, United StatesContact: Study CoordinatorTaking people
- UT Southwestern (Site 0092)Dallas, United StatesContact: Study CoordinatorTaking people
- Intermountain Health Cancer Center Saint Joseph (Site 0062)Denver, United StatesContact: Study CoordinatorTaking people
- Rocky Mountain Cancer Centers (RMCC) (Site 8006)Denver, United StatesContact: Study CoordinatorTaking people
- Texas Oncology - Northeast Texas (Site 8002)Flower Mound, United StatesContact: Study CoordinatorTaking people
- Florida Cancer Specialists - South (Site 7004)Fort Myers, United StatesContact: Study CoordinatorTaking people
- Fort Wayne Medical Oncology and Hematology (Site 0084)Fort Wayne, United StatesContact: Study CoordinatorTaking people
- JPS Oncology and Infusion Center (Site 0083)Fort Worth, United StatesContact: Study CoordinatorTaking people
- Providence Medical Foundation (Site 0080)Fullerton, United StatesContact: Study CoordinatorTaking people
- Banner MD Anderson Cancer Center (Site 0066)Gilbert, United StatesContact: Study CoordinatorTaking people
- Altru Health System (Site 0057)Grand Forks, United StatesContact: Study CoordinatorTaking people
- Intermountain Health St. Mary's Regional Hospital (Site 0054)Grand Junction, United StatesContact: Study CoordinatorTaking people
- St Francis Cancer Center (Site 0093)Greenville, United StatesContact: Study CoordinatorTaking people
- Hackensack Univ Medical Center (HUMC) (Site 0007)Hackensack, United StatesContact: Study CoordinatorTaking people
- Bioresearch Partner (Site 0072)Hialeah, United StatesContact: Study CoordinatorTaking people
- Kelsey-Seybold Clinic (Site 0042)Houston, United StatesContact: Study CoordinatorTaking people
- Kelsey-Seybold Clinic (Site 0088)Houston, United StatesContact: Study CoordinatorTaking people
- Oncology Consultants P.A. (Site 0073)Houston, United StatesContact: Study CoordinatorTaking people
- Franciscan Health (Site 0077)Indianapolis, United StatesContact: Study CoordinatorTaking people
- Mayo Clinic Hospital (Site 0013)Jacksonville, United StatesContact: Study CoordinatorTaking people
- Saint Luke's Cancer Institute (Site 0059)Kansas City, United StatesContact: Study CoordinatorTaking people
- Tennessee Cancer Specialists (Site 7001)Knoxville, United StatesContact: Study CoordinatorTaking people
- Optum Care Cancer Center (Site 0050)Las Vegas, United StatesContact: Study CoordinatorTaking people
- Cancer Partners of Nebraska (Site 0068)Lincoln, United StatesContact: Study CoordinatorTaking people
- MemorialCare Health System - Long Beach Medical Center (Site 9556)Long Beach, United StatesContact: Study CoordinatorTaking people
- Texas Tech University Health Sciences Center (Site 0087)Lubbock, United StatesContact: Study CoordinatorTaking people
- University of Wisconsin-Madison (Site 0024)Madison, United StatesContact: Study CoordinatorTaking people
- Bon Secours Cancer Institute at St. Francis (Site 0048)Midlothian, United StatesContact: Study CoordinatorTaking people
- El Camino Hospital Cancer Center (Site 0096)Mountain View, United StatesContact: Study CoordinatorTaking people
- Intermountain Medical Center (Site 0074)Murray, United StatesContact: Study CoordinatorTaking people
- Nashville General Hospital (Site 0017)Nashville, United StatesContact: Study CoordinatorTaking people
- SCRI Oncology Partners (Site 7005)Nashville, United StatesContact: Study CoordinatorTaking people
- Vanderbilt-Ingram Cancer Center (Site 0038)Nashville, United StatesContact: Study CoordinatorTaking people
- Rutgers Cancer Institute of New Jersey (Site 0076)New Brunswick, United StatesContact: Study CoordinatorTaking people
- Ochsner Clinic Foundation (Site 0021)New Orleans, United StatesContact: Study CoordinatorTaking people
- City of Hope Cancer Center - Atlanta (Site 0102)Newnan, United StatesContact: Study CoordinatorTaking people
- Hoag Memorial Hospital Presbyterian (Site 0010)Newport Beach, United StatesContact: Study CoordinatorTaking people
- Virginia Oncology Associates (VOA) (Site 8008)Norfolk, United StatesContact: Study CoordinatorTaking people
- Mayo Clinic Cancer Center (Site 0034)Phoenix, United StatesContact: Study CoordinatorTaking people
- Renown Regional Medical Center (Site 0041)Reno, United StatesContact: Study CoordinatorTaking people
- Oncology and Hematology Associates of Southwest Virginia (BRCC) (Site 8005)Roanoke, United StatesContact: Study CoordinatorTaking people
- Texas Oncology - San Antonio (Site 8004)San Antonio, United StatesContact: Study CoordinatorTaking people
- Fred Hutchinson Cancer Center (Site 0069)Seattle, United StatesContact: Study CoordinatorTaking people
- Louisiana State University Health Sciences Shreveport (Site 0053)Shreveport, United StatesContact: Study CoordinatorTaking people
- Avera McKennan Hospital (Site 0002)Sioux Falls, United StatesContact: Study CoordinatorTaking people
- Cancer Care Northwest (Site 0003)Spokane, United StatesContact: Study CoordinatorTaking people
- Washington University Siteman Cancer Center (Site 0031)St Louis, United StatesContact: Study CoordinatorTaking people
- Florida Cancer Specialists - North (Site 7002)St. Petersburg, United StatesContact: Study CoordinatorTaking people
- Northwest Medical Specialties, PLLC (Site 0067)Tacoma, United StatesContact: Study CoordinatorTaking people
- Northwest Cancer Specialists (Compass Oncology) (Site 8010)Tigard, United StatesContact: Study CoordinatorTaking people
- University of Arizona Cancer Center (Site 0035)Tucson, United StatesContact: Study CoordinatorTaking people
- New England Cancer Specialists (Site 0051)Westbrook, United StatesContact: Study CoordinatorTaking people
- Helios Clinical Research (Site 0061)Whittier, United StatesContact: Study CoordinatorTaking people
- Avera Cancer Institute - Yankton (Site 0089)Yankton, United StatesContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
Researchers are looking for new ways to treat types of breast cancer that are both:
Read full original descriptionShow less
* High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone.
Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread.
The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy:
* Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
The 2 groups in the trial
- sac-TMTTreatment being tested
Participants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) + IV pembrolizumab 200 mg every 3 weeks (Q3W), for 12 weeks; then receive IV pembrolizumab 200 mg Q3W and IV carboplatin area under the curve (AUC) 1.5 + IV paclitaxel 80 mg/m\^2 once weekly, for 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant treatment of physician's choice (TPC) may be administered to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); capecitabine 1000-1250 mg/m\^2 oral twice daily on days 1-14 and 22-35 each cycle for 4 six-week cycles; or doxorubicin 60mg/m\^2 (or epirubicin 90 mg/m\^2) IV infusion Q3W/Q2W + cyclophosphamide 600 mg/m\^2 IV infusion Q3W/Q2W for 4 doses.
Treatment: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, and Olaparib
- ChemotherapyExisting treatment, for comparison
Participants receive IV carboplatin AUC 1.5 and paclitaxel 80 mg/m\^2 once weekly, alongside pembrolizumab 200 mg Q3W, for 6 weeks; then receive IV pembrolizumab 200 mg Q3W alongside IV cyclophosphamide 600 mg/m\^2 Q3W and either doxorubicin 60 mg/m\^2 Q3W or epirubicin 90 mg/m\^2 Q3W, for up to 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options are olaparib 300 mg oral BID for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); or capecitabine 1000-1250 mg/m\^2 oral BID on days 1-14 and 22-35 each cycle for 4 six-week cycles.
Treatment: Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, and Olaparib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
- Plain-language title
- Testing sacituzumab tirumotecan with pembrolizumab before surgery for early breast cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 10 November 2026